RJA
ARNA

Raymond James & Associates’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Raymond James & Associates’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,825
Closed -$329K – 4313
2021
Q2 		$329K Sell
4,825
-4,671
-49% -$304K ﹤0.01% 3375
2021
Q1 		$659K Buy
9,496
+891
+10% +$68.6K ﹤0.01% 2806
2020
Q4 		$661K Sell
8,605
-3,448
-29% -$258K ﹤0.01% 2619
2020
Q3 		$901K Buy
12,053
+726
+6% +$48.4K ﹤0.01% 2237
2020
Q2 		$713K Buy
11,327
+32
+0.3% +$1.76K ﹤0.01% 2365
2020
Q1 		$474K Sell
11,295
-440
-4% -$20.2K ﹤0.01% 2456
2019
Q4 		$533K Sell
11,735
-4,048
-26% -$191K ﹤0.01% 2685
2019
Q3 		$722K Sell
15,783
-279
-2% -$15.7K ﹤0.01% 2396
2019
Q2 		$942K Sell
16,062
-1,371
-8% -$70.9K ﹤0.01% 2251
2019
Q1 		$782K Buy
+17,433
New +$800K ﹤0.01% 2349
2017
Q2 		– Sell
-1,160
Closed -$17K – 3461
2017
Q1 		$17K Buy
+1,160
New +$17.2K ﹤0.01% 3213
2014
Q2 		– Sell
-3,205
Closed -$202K – 2244
2014
Q1 		$202K Buy
+3,205
New +$213K ﹤0.01% 2068

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Raymond James & Associates's ARNA Position: Q3 2021 in Review

Raymond James & Associates sold out of Arena Pharmaceuticals Inc (ARNA) in Q3 2021, closing a stake of 4,825 shares — an estimated $329K sold.

Raymond James & Associates first reported a position in ARNA in Q1 2014 and held it in 12 quarters. The position peaked at $942K in Q2 2019. 235 funds tracked by Wall St. Rank hold ARNA as of Q3 2021.

  • Raymond James & Associates reported no remaining Arena Pharmaceuticals Inc position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 4,825 Arena Pharmaceuticals Inc shares in Q3 2021, an estimated $329K.
  • Raymond James & Associates first reported a position in Arena Pharmaceuticals Inc in Q1 2014 and held it in 12 quarters.
  • Raymond James & Associates's Arena Pharmaceuticals Inc position peaked at $942K in Q2 2019.
  • 235 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.